RAD17

Across TCGA pan-cancer cohorts, RAD17 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated RAD17 data layer compared with 28 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher RAD17 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated RAD17 expression acts as an unfavorable survival marker, although some lineages such as HNSC and CCRCC show a favorable association.

HNSC, CCRCC, and LUAD are the cancer types where RAD17 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	II,III,IV	0.953	0.776	.002	14	view →
CCRCC	DFS	Tertile	II,III,IV	1.000	0.773	.018	10	view →
LUAD	DFS	Median	All	0.867	0.966	.018	7	view →
UCEC	OS	Median	All	0.968	0.855	.024	6	view →
PDAC	DFS	Median	III,IV	0.910	0.597	.024	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

RAD17–HNSC (OS)

Open the HNSC breakdown →